Table 1. Patients and tumor characteristics.
| Characteristics | Values |
|---|---|
| Gender | |
| Male | 83 (82.2) |
| Female | 18 (17.8) |
| Age (years) | 64 [36–81] |
| ECOG-PS score | |
| ≤1 | 92 (91.1) |
| >1 | 9 (8.9) |
| Primary tumor location | |
| Lung | 36 (35.6) |
| Non-lung | 65 (64.4) |
| Histologic subtype | |
| Adenocarcinoma | 48 (47.5) |
| Squamous cell carcinoma | 23 (22.8) |
| Other | 30 (29.7) |
| Number of metastases in the lung | |
| ≤2 | 95 (94.1) |
| >2 | 6 (5.9) |
| Distribution of metastasis | |
| Lung only | 71 (70.3) |
| Extrapulmonary and lung | 30 (29.7) |
| Time from diagnosis to lung metastasis (years) | |
| <2 | 48 (47.5) |
| ≥2 | 53 (52.5) |
| Dose (Gy/fraction) | |
| 50/5 | 12 (8.5) |
| 50/10 | 28 (19.9) |
| 60/10 | 92 (65.2) |
| 70/10 | 9 (6.4) |
| BED10 (Gy) | 96 [75–119] |
| Diameter of tumor (mm) | 13.5 [5.0–68.0] |
| Pulmonary lobe | |
| Superior lobe of left lung | 26 (18.4) |
| Inferior lobe of left lung | 38 (27.0) |
| Superior lobe of right lung | 34 (24.1) |
| Inferior lobe of right lung | 35 (24.8) |
| Middle lobe of right lung | 8 (5.7) |
| Adjuvant systemic therapy before SBRT | |
| Surgery | 7 (6.9) |
| Surgery + chemotherapy/targeted therapy/radiochemotherapy | 39 (38.6) |
| Surgery + chemotherapy + targeted therapy/immunotherapy | 19 (18.8) |
| Surgery + chemotherapy + immunotherapy + targeted therapy/radiation | 13 (12.9) |
| Radiofrequency ablation or chemotherapy ± targeted therapy | 23 (22.8) |
Data are presented as median [range] or n (%). ECOG-PS, Eastern Cooperative Oncology Group performance status; BED, biological equivalent dose; SBRT, stereotactic body radiotherapy.